Jean‐luc Raoul
#150,229
Most Influential Person Now
Jean‐luc Raoul's AcademicInfluence.com Rankings
Jean‐luc Raoulmedical Degrees
Medical
#2889
World Rank
#3333
Historical Rank
Oncology
#192
World Rank
#198
Historical Rank
Pharmacology
#328
World Rank
#379
Historical Rank
Jean‐luc Raoulphilosophy Degrees
Philosophy
#8272
World Rank
#11618
Historical Rank
Logic
#5308
World Rank
#6697
Historical Rank
Download Badge
Medical Philosophy
Jean‐luc Raoul's Degrees
- PhD Pharmacology Université Paris Cité
- Doctorate Medicine Université Paris Cité
Why Is Jean‐luc Raoul Influential?
(Suggest an Edit or Addition)Jean‐luc Raoul's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sorafenib in advanced hepatocellular carcinoma. (2008) (5771)
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018) (5681)
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. (2011) (4954)
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011) (2225)
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (2018) (1420)
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial (2016) (749)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. (2012) (707)
- Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) (649)
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) (554)
- Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. (2011) (490)
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. (2017) (479)
- Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. (2013) (393)
- Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. (1998) (297)
- Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. (2008) (292)
- Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. (2014) (291)
- Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. (2019) (282)
- Prospective randomized trial of chemoembolization versus intra‐arterial injection of 131I‐labeled–iodized oil in the treatment of hepatocellular carcinoma (1997) (273)
- Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. (2004) (270)
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma (2012) (264)
- Treatment of intermediate-stage hepatocellular carcinoma (2014) (250)
- Dosimetry Based on 99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90Y-Loaded Glass Microspheres: Preliminary Results (2012) (242)
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors (2009) (232)
- Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. (1994) (199)
- Research reporting standards for radioembolization of hepatic malignancies. (2011) (180)
- Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept (2013) (170)
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). (2009) (168)
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. (2012) (160)
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. (2017) (156)
- High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation (2014) (145)
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. (2018) (141)
- Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. (1988) (135)
- Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. (2015) (125)
- A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. (2002) (124)
- Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. (2005) (120)
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts (2017) (120)
- Personalized Dosimetry with Intensification Using 90Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis (2015) (116)
- Adjuvant intra‐arterial injection of iodine‐131–labeled lipiodol after resection of hepatocellular carcinoma (2003) (112)
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. (2018) (110)
- How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective (2014) (108)
- Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin (1992) (105)
- Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. (2004) (105)
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. (2012) (103)
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study) (2011) (99)
- Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. (2009) (97)
- Dyschezia and rectocele—A marriage of convenience? (1993) (95)
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (2011) (93)
- 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
- Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. (1992) (91)
- Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. (2013) (90)
- Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment (2017) (90)
- Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. (2008) (90)
- How accurate is clinical examination in diagnosing and quantifying pelvirectal disorders? A prospective study in a group of 50 patients complaining of defecatory difficulties (1993) (89)
- A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802) (2005) (88)
- Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. (1988) (84)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study (2016) (84)
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial (2007) (82)
- Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. (2016) (79)
- Prognostic value of PDL1 expression in pancreatic cancer (2016) (79)
- Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. (2005) (78)
- Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. (2010) (77)
- Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) (2010) (76)
- Use of chemotherapy near the end of life: what factors matter? (2016) (75)
- Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort (2015) (72)
- Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. (2010) (72)
- Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting? (2013) (71)
- An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). (2016) (70)
- Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. (2007) (70)
- Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. (2018) (68)
- Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen) (2002) (68)
- Salvage Esophagectomy after Unsuccessful Curative Chemoradiotherapy for Squamous Cell Cancer of the Esophagus (1998) (66)
- Natural history of hepatocellular carcinoma and current treatment options. (2008) (66)
- Cystic duct clip migration into the common bile duct: a complication of laparoscopic cholecystectomy treated by endoscopic biliary sphincterotomy. (1992) (65)
- Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. (2001) (64)
- [Nonsurgical treatment of hepatocellular carcinoma]. (1999) (64)
- Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials (2008) (64)
- Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. (1995) (62)
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. (2009) (61)
- Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. (1992) (59)
- Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts (2017) (58)
- Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma (2012) (57)
- A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. (2001) (56)
- Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides (2010) (53)
- Absence of human papillomavirus DNA detected by polymerase chain reaction in French patients with esophageal carcinoma. (1995) (52)
- Defecatory disorders, anorectal and pelvic floor dysfunction: a polygamy? (1992) (52)
- Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial (2006) (49)
- Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study (2009) (48)
- Immunological study in primary intestinal lymphangiectasia. (1994) (48)
- Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. (2003) (47)
- High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer (2002) (46)
- Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma (2014) (46)
- A 25-gene classifier predicts overall survival in resectable pancreatic cancer (2017) (45)
- Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort. (2015) (45)
- Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. (2015) (45)
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial (2016) (45)
- Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. (2009) (44)
- Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C results from a French multicenter study (2015) (44)
- Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. (1998) (44)
- Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer (2010) (43)
- Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization (2012) (42)
- Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis (2019) (42)
- Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. (2002) (41)
- First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation (2010) (40)
- Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective (2013) (40)
- Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. (2011) (40)
- Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer (2015) (40)
- PANERB study: Panitumumab after cetuximab-based regimen failure. (2010) (39)
- Carcinoma of the ampulla of Vater: prognostic factors after curative surgery: a series of 45 cases. (1997) (39)
- Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study (2011) (38)
- Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. (2007) (38)
- Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). (2010) (37)
- Preoperative treatment of hepatocellular carcinoma with intra‐arterial injection of 131I‐labelled lipiodol (2003) (36)
- In vitro demonstration of synergy between radionuclide and chemotherapy. (1998) (36)
- International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. (2008) (36)
- Characterization of subepithelial lesions of the stomach and esophagus by contrast-enhanced EUS: A retrospective study (2018) (36)
- Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results (2013) (35)
- Utility of Quantitative 99mTc-MAA SPECT/CT for 90yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach (2011) (33)
- 3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma (2007) (33)
- Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (2018) (32)
- A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. (2020) (32)
- 3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) (2007) (30)
- Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. (2011) (30)
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. (2012) (30)
- CASE REPORT: Adenocarcinoid of the Appendix Vermiformis: Complete and Persistent Remission After Chemotherapy (Folfox) of a Metastatic Case (2002) (30)
- SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (2017) (29)
- Cementoplasty for painful bone metastases: a series of 42 cases (2012) (29)
- Expression of MAGE genes in esophageal squamous-cell carcinoma. (1997) (29)
- Pseudoaneurysms and bleeding pseudocysts in chronic pancreatitis: Radiological findings and contribution to diagnosis in 8 cases (2005) (29)
- Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. (2016) (28)
- Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus (1995) (28)
- Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). (2011) (28)
- Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery (2015) (28)
- Adjuvant Intraarterial Injection of 131I-Labeled Lipiodol After Resection of Hepatocellular Carcinoma: Progress Report of a Case-Control Study with a 5-Year Minimal Follow-up (2008) (27)
- [Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol]. (1986) (26)
- Ethanol lavage of 14 mucinous cysts of the pancreas: A retrospective study in two tertiary centers (2012) (26)
- Current options and future possibilities for the systemic treatment of hepatocellular carcinoma (2019) (25)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial (2008) (25)
- Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) (2005) (25)
- Bone metastasis revealing hepatocellular carcinoma: a report of three cases with a long clinical course. (1995) (25)
- A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 ) (2009) (25)
- Automation of labelling of Lipiodol with high-activity generator-produced 188Re. (2011) (25)
- Sensitive and easy screening for circulating tumor cells by flow cytometry. (2019) (25)
- Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case–control study (2018) (24)
- Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. (2020) (24)
- Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol (2008) (24)
- Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort (2017) (24)
- Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer (2006) (24)
- FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. (2019) (24)
- 131-iodine Lipiodol therapy in hepatocellular carcinoma. (2009) (24)
- Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. (1998) (23)
- Constipation after rectopexy for rectal prolapse (1993) (23)
- Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma (2014) (23)
- Ex vivo right trisegmentectomy with reconstruction of inferior vena cava and "flop" reimplantation. (2002) (22)
- An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma (2017) (22)
- Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response (2017) (22)
- Feasibility of Intratumoral Confocal Microscopy under Endoscopic Ultrasound Guidance (2012) (22)
- Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. (2017) (22)
- Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer (2016) (21)
- A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor (2014) (21)
- 67 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): SUBANALYSIS OF SHARP TRIAL BASED ON BARCELONA CLINIC LIVER CANCER (BCLC) STAGE (2009) (21)
- Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years (2012) (21)
- High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases? (2008) (20)
- [Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study]. (1994) (20)
- Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (2012) (19)
- Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma (2003) (18)
- Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). (2012) (18)
- Association of cisplatin and intra-arterial injection of 131I-lipiodol in treatment of hepatocellular carcinoma: results of phase II trial. (2006) (18)
- Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy (2004) (18)
- Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. (2016) (18)
- [Prognosis and prognostic factors of hemorrhage by rupture of varices in cirrhotic patients in the era of endoscopic sclerotherapy]. (1991) (17)
- Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. (2010) (17)
- Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. (2014) (17)
- One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. (2014) (17)
- Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. (2005) (17)
- 46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803 (2003) (16)
- Radio(chemo)therapy in Elderly Patients with Esophageal Cancer: A Feasible Treatment with an Outcome Consistent with Younger Patients (2014) (16)
- FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. (2018) (15)
- Gastric bypass for malignant esophagotracheal fistula: a series of 21 cases. (1998) (15)
- Phase III, Randomized, Double-blind Trial of Sunitinib Versus Placebo in Patients With Progressive, Well-differentiated Pancreatic Islet Cell Tumours (2009) (15)
- Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma (2017) (15)
- ¹³¹I-labeled lipiodol-induced interstitial pneumonia: a series of 15 cases. (2011) (15)
- Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma (2013) (15)
- Calcifying pancreatitis of a congenital short pancreas: a case report with successful endoscopic papillotomy. (1987) (15)
- FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA). (2015) (14)
- Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). (2006) (13)
- Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. (2010) (13)
- Hepatocellular carcinoma scoring and staging systems. Do we need new tools? (2016) (13)
- Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer (2021) (12)
- Scintigraphic assessment of indium-111-labeled granulocyte splenic pooling: a new approach to inflammatory bowel disease activity. (1990) (12)
- Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). (2013) (12)
- Management of Esophageal Carcinoma Associated with Cirrhosis: A Retrospective Case-Control Analysis (2009) (12)
- How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma (2016) (12)
- Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE. (2018) (12)
- Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). (2010) (12)
- Intestinal lymphangiectasia: lack of efficacy of antiplasmin therapy? (1991) (12)
- NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization (2017) (12)
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC) (2005) (12)
- Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover. (2016) (11)
- Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients (2016) (11)
- 289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC) (2003) (11)
- Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus. (1997) (11)
- LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301) (2008) (11)
- [Glucagonoma: a recent series of 7 cases]. (2004) (10)
- Acrokeratosis paraneoplastica (Bazex' syndrome) associated with metastatic squamous cell esophageal carcinoma. (2008) (10)
- Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC) (1999) (10)
- A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. (2017) (10)
- [Cystic tumors and endocrine tumor of the pancreas. An unusual association]. (1993) (10)
- [Radioembolisation for hepatocellular carcinoma]. (2011) (9)
- Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment (2006) (9)
- Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema (2014) (9)
- Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients (2015) (9)
- [Chemotherapy combined with Lipiodol. In vitro study of the kinetics of release of adriamycin]. (1989) (9)
- Tonsillar metastasis revealing signet-ring cell carcinoma of the rectum. (2008) (9)
- [Massive hepatic necrosis secondary to treatment of hepatocellular carcinoma by percutaneous alcoholization]. (1998) (9)
- How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017? (2017) (9)
- Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study (2020) (8)
- In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results. (2013) (8)
- Recent Advances in Bioinformatics Reveal the Molecular Heterogeneity of Hepatocellular Carcinoma (2014) (8)
- [Is the identification of acute biliary and alcoholic pancreatitis by early pancreatic enzyme assay possible?]. (1994) (8)
- Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo. (2011) (7)
- [Hepatocellular carcinoma: Increase in incidence or future plague?] (2018) (7)
- [Esophageal cancer and endoscopic sclerosis of esophageal varices: a fortuitous association?]. (1988) (7)
- Usefulness of hepatic artery injection of iodized oil and 131I-labeled iodized oil before the therapeutic decision in hepatocellular carcinoma. (1993) (7)
- Unusual presentation of a case of brain abscess after endoscopic injection sclerotherapy of esophageal varices. (1991) (7)
- Nomogram of the Barcelona Clinic Liver Cancer System: external validation in European patients (2016) (7)
- Indium scanning in assessment of acute Crohn's disease (1993) (7)
- [Does manometric megarectum have a symptomatic role in patients complaining of dyschezia?]. (1993) (7)
- Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma (2012) (7)
- Recurrent cholangitis caused by the migration of pancreatic calculi associated with pancreas divisum. (1993) (7)
- Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). (2016) (7)
- Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/α-fetoprotein (AFP) and bilirubin (bil) levels. (2010) (7)
- Tu1542 EUS Guided Hepatico-Gastrostomy Using a New Design Partially Covered Stent (GIOBOR Stent) (2012) (7)
- [Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?]. (2014) (6)
- Non‐invasive diagnostic criteria for hepatocellular carcinoma: The value of contrast washout at imaging and the death of alpha‐fetoprotein (2011) (6)
- FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. (2016) (6)
- Chemoradiotherapy for cancer of the esophagus: contribution of the leucovorin, 5-fluorouracil bolus, and infusion-cisplatin-radiotherapy schedule starting with two neoadjuvant chemotherapy cycles: results from a pilot study. (2009) (6)
- Relationship between gastric mucosal changes and hemodynamic patterns in alcoholic cirrhosis. A prospective study. (1993) (6)
- [Black esophagus. Three new cases]. (1993) (6)
- Effect of the rate of artificial insemination and paternity knowledge on the genetic gain for French meat sheep breeding programs (2020) (6)
- Acute ischemia of the lower limb during chemotherapy for testicular cancer: A report of two cases (2009) (6)
- OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). (2014) (6)
- 6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial (2009) (6)
- Management of nonsteroidal anti-inflammatory drug-induced upper gastrointestinal bleeding and perforation. (1995) (6)
- [Splenogastrorenal shunt in portal hypertension: a little known entity. Study of 6 cases and review of the literature]. (1987) (6)
- Distant Lymph Node Metastases in Gastroesophageal Junction Adenocarcinoma: Impact of Endoscopic Ultrasound-Guided Fine-Needle Aspiration (2013) (6)
- Response to 'the flexible therapeutic approach to the BCLC B stage': Time for scoring systems? (2017) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Definitive chemo-radiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study (2007) (6)
- Constipation after rectopexy for rectal prolapse where is the obstruction (1992) (6)
- Prognostic Value of Molecular Subtypes in Pancreatic Cancer. (2017) (6)
- Bazex Syndrome Revealing a Gastric Cancer (2014) (6)
- Usefulness of the MESH score in a European hepatocellular carcinoma cohort (2017) (5)
- An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value (2017) (5)
- Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. (2016) (5)
- Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) (2012) (5)
- Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data. (2010) (5)
- Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma (2017) (5)
- Is Chemoembolisation of Value in Inoperable Primary Hepatocellular Carcinoma (1998) (5)
- Use of chemotherapy near the end of life for solid cancers: What factors matter? (2016) (5)
- [Umbilical metastasis of an hepatocellular carcinoma]. (1998) (5)
- Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada. (2018) (5)
- Solid Pseudopapillary Tumor of the Pancreas: One Case with a Metastatic Evolution in a Caucasian Woman (2015) (5)
- Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases (2014) (5)
- Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis (2021) (5)
- [Course of patients after eradication of esophageal varices by sclerotherapy: influence of the site of the first hemorrhage]. (1987) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- Local injections of granulocyte-macrophage colony-stimulating factor (Gm-CSF) for the treatment of radiation-induced mucosa ulcers. (2003) (4)
- Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components (2021) (4)
- Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper (2022) (4)
- A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study (2017) (4)
- [Villous tumors of the Wirsung's duct and pancreatic intraductal adenocarcinoma: interrelation or accidental association?]. (1992) (4)
- [Endoscopic treatment and extracorporeal lithotripsy in chronic calcifying pancreatitis. Preliminary results in 16 patients]. (1993) (4)
- Neuroendocrine tumors and CUP (2012) (4)
- HCC classification and HCC scoring system: a win‐win combination for prognosis and treatment recommendations (2016) (4)
- Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study (2021) (4)
- [Acinous-cell carcinoma of a metastatic pancreas treated by chemotherapy]. (2002) (4)
- Imaging of inflammatory bowel disease (IBD) and scintigraphic assessment of resected colon: comparison of 111 In-oxine and 99mTC HMPAO leucocyte labelling. (1990) (4)
- Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial. (2017) (4)
- Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials (2007) (4)
- Retrorectal Mucinous Adenocarcinoma Arising from a Tailgut Cyst: A Case Report (2021) (4)
- Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors (2021) (4)
- Hepatocellular Carcinoma: Slow Progress in a Booming Epidemic. (2017) (4)
- Limitations of hyperselective intraarterial injections for the treatment of hepatocellular carcinoma. (1996) (4)
- Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer (2007) (3)
- [Proton pump inhibitors and cancers: A hazardous association?] (2020) (3)
- FRI-494-Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis (2019) (3)
- 6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (3)
- What is the benefit for patients suffering from metastatic colorectal cancer (mCRC) after bevacizumab-based regimen (BBR), cetuximab-based regimen (CBR), and panitumumab (P)? (2011) (3)
- [Diagnostic management of squamous cell carcinoma of the esophagus]. (1999) (3)
- Staging of hepatocellular carcinoma: BCLC system, what else! (2016) (3)
- Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. (2018) (3)
- P976 RETREATMENT WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE): THE ABCR SCORE, AN AID TO THE DECISION-MAKING PROCESS (2014) (3)
- ‘Tomudex’ (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination (1999) (3)
- Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results (2021) (3)
- Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. (2006) (3)
- Gastric ulcer and cholestasis following injection therapy of bleeding duodenal ulcers. (1991) (3)
- Significance of lymph node involvement in local recurrence of colorectal cancer (2019) (3)
- LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial. (2017) (3)
- [Acute alithiasic cholecystitis: gallbladder site of Staphylococcus aureus septicemia]. (1990) (3)
- [Adenocarcinoma of Brunner's glands: an entity exceptionally described. Report of a case]. (1995) (3)
- Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer (2021) (3)
- Reply to: ''Repeated transarterial chemoembolization: An overfitting effort?''. (2015) (2)
- Longitudinal analysis of the quality of life (QoL) within a randomized phase III trial: Octreotide versus placebo for the patients having advanced hepato-cellular carcinoma (HCC). (2016) (2)
- Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003–03 trial) (2005) (2)
- Why is pancreatic cancer difficult to treat in the elderly (2012) (2)
- Acute respiratory distress syndrome (ARDS) after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin: a case report (2021) (2)
- A CDM Standard to Guide Implementation in Europe (2008) (2)
- Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence. (2019) (2)
- Zollinger-Ellison syndrome, antisecretory treatment, and body weight (1992) (2)
- 583 TUMOR RESPONSE IN A PHASE 2 STUDY OF FIRST-LINE BRIVANIB IN HEPATOCELLULAR CARCINOMA (HCC): COMPARISON OF MODIFIED WHO AND MODIFIED RECIST CRITERIA (2010) (2)
- Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma. (2019) (2)
- New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations (2022) (2)
- “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort (2020) (2)
- Radiation-induced oesophageal carcinoma after breast carcinoma: A report of five cases including three successfully treated by radiochemotherapy (2007) (2)
- Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. (2013) (2)
- Intermediate-stage HCC—upfront resection can be feasible (2015) (2)
- [Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases]. (1991) (2)
- New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice (2005) (2)
- Clubbing and Hypertrophic Osteoarthropathy in Two Patients Taking Long-Term Bevacizumab for Metastatic Colorectal Cancer (2011) (2)
- Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal). (2019) (2)
- [Massive lower digestive hemorrhages. Diagnostic and therapeutic approach]. (1995) (2)
- Hepatocellular carcinoma (2001) (2)
- [Gastroduodenal invagination. Radio-endoscopic aspects]. (1990) (2)
- Transient Vision Loss − A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases (2021) (2)
- Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC) (2004) (2)
- Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET) (2011) (2)
- COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19) (2022) (2)
- Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial). (2018) (2)
- Chemotherapy for metastatic colorectal cancer: Why not take a break when it works? (2004) (2)
- Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. (2019) (2)
- Medical oncologists must get more involved in systemic treatment. (2019) (1)
- Intermediate stage treatment: Is TACE enough? (2018) (1)
- Abstract 2632: Clinical validation of circulating DNA analysis for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy (2016) (1)
- Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas (2010) (1)
- [Radiologic aspects of a case of Waldmann's disease]. (1990) (1)
- Relationship between high dose irinotecan (260mg/m2) and response rate, without increased toxicities in metastatic colorectal cancer (MCRC) combination with bi-weekly 5FU/FA in a phase II study (2001) (1)
- Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study (2020) (1)
- Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation (2014) (1)
- Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS (2018) (1)
- Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics (2014) (1)
- Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma (2013) (1)
- Efficacity and safety of panitumumab in mCRC patients: A post-AMM OMIT study. (2012) (1)
- 743TiPAN INTERNATIONAL OBSERVATIONAL STUDY TO ASSESS THE USE OF SORAFENIB AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS. (2014) (1)
- Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study. (2015) (1)
- [Gastroduodenal duplication and chronic hepatitis: fortuitous association?]. (1991) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- [Chronic diarrhea during treatment with Veinotonyl 75]. (1994) (1)
- EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST” (2016) (1)
- P977 UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED BY TRANSARTERIAL CHEMOEMBOLIZATION (TACE): AFTER TWO SESSIONS, ART OR ABCR SCORES TO GUIDE THE DECISION MAKING PROCESS? (2014) (1)
- P1338 : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): optimis (2015) (1)
- Influence of portal systemic shunting on systemic hemodynamics and plasma glucagon level changes in cirrhotic patients (1988) (1)
- BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report (2019) (1)
- Prognostication of HCC under sorafenib: Is it always possible? (2019) (1)
- Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis (2022) (1)
- Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA). (2004) (1)
- To TACE or not to TACE? Lessons from a negative trial. (2017) (1)
- P0376 : Stratification of hepatocellular carcinoma. The prognostic score NIACE, an additional aid to the Barcelona Clinic Liver Cancer (BCLC) staging system? Multicenter study (2015) (1)
- FOLFIRI-cetuximab: A multicenter phase II proof-of-concept study of a tailored triple combination therapy for safe dose intensification. (2014) (1)
- Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old (2015) (1)
- Iconography : Longitudinal quality of life study in patients with metastatic gastric cancer (2008) (1)
- [Treatment of hepatocellular carcinoma with tamoxifen]. (1996) (1)
- "RESPIRATION" DES AMES DE POUTRES DE PONT - ETUDE PARAMETRIQUE ET METHODE SIMPLIFIEE DE VERIFICATION A LA FATIGUE SOUS CONTRAINTES NORMALES (1996) (1)
- A letter of response to comments on 'A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers'. (2021) (1)
- Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastasis (LM) from colorectal cancer (CRC). (2004) (1)
- Solid pancreatic tumors in patients younger than 40 years old--experience of a French comprehensive cancer center. (2015) (1)
- [Hemoperitoneum secondary to spontaneous rupture of metastatic liver of a testicular germ cell tumor]. (2007) (1)
- Sa1546 Evaluation of 2 New EUS-Needles « PRO Core 21 and 20 Gauges » in Patients With Pancreatic Masses. Results of a Randomized Study (2012) (1)
- [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma]. (2015) (1)
- [Therapeutic indications]. (1999) (1)
- Novel therapeutic targets for pancreatic adenocarcinoma revealed by a multi-omics analysis of patient-derived xenografts (2017) (1)
- [Results of portacaval shunt after failure of sclerotherapy in patients with cirrhosis]. (1992) (1)
- Preliminary results of a randomized phase III trial comparing streptozotocin plus fluorouracil versus interferon for metastatic carcinoid tumors (FNCLCC - FFCD 9710). (2006) (1)
- [Gastric and duodenal metastases of esophageal cancer]. (1990) (1)
- Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes. (2015) (0)
- Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis (2022) (0)
- Looking for synergy or additivity between 188Re and sorafenib on hepatoma cell lines. (2012) (0)
- OP-02 Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: A new personalized promising concept (2013) (0)
- 1003 IMPACT OF MAA SPECT/CT IN THE PREDICTION OF RESPONSE, SURVIVAL AND IN THE TREATMENT PLANNING FOR HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY 90Y-LOADED GLASS MICROSPHERES (2012) (0)
- [Squamous cell carcinoma of the esophagus: palliative and maintenance treatment]. (1999) (0)
- PTK7 Overexpression is Associated with Reduced Metastasis-Free Survival (MFS) in Colorectal Cancer (2012) (0)
- 1354PA SCORE TO GUIDE THE DECISION FOR RETREATMENT AFTER 2 LINES OF SYSTEMIC PALLIATIVE THERAPY FOR SOLID TUMORS. A PROSPECTIVE STUDY. (2014) (0)
- Abstract B72: Pancreatic cancer cell drives stroma composition (2016) (0)
- Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). (2009) (0)
- 505PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial (2017) (0)
- [Does sclerotherapy of esophageal varices induce cholestasis?]. (1986) (0)
- [Palliative treatment of esophageal carcinoma: chemotherapy and palliative care]. (2005) (0)
- Author's reply: Preoperative treatment of hepatocellular carcinoma with intra‐arterial injection of 131I‐labelled lipiodol (Br J Surg 2003; 90: 1379‐1383) (2004) (0)
- Prediction of benefit after TACE : subclassifications or scoring systems ? (2017) (0)
- PD-0007A TRIPLE COMBINATION TAILORED THERAPY (FOLFIRI-CETUXIMAB) FOR SAFE DOSE INTENSIFICATION: A MULTICENTER PHASE II PROOF-OF-CONCEPT STUDY. (2014) (0)
- Chemotherapy for advanced or metastatic biliary tract cancer (ABC): Results of a single-center experience for 78 patients over three years. (2010) (0)
- [Chronic duodenal ulcer. Epidemiology, physiopathology, diagnosis, development, treatment]. (1992) (0)
- Geriatric Profile of Elderly Patients Treated For Pancreatic Cancer: The Oncogepan Database (2017) (0)
- Glutathione-S-Transferases (GST) Activity Decreases Survival in Chemoradiotherapy for Esophageal Cancer (2008) (0)
- Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma (2016) (0)
- Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure (2023) (0)
- Loco-regional treatments of unresectable hepatocellular carcinoma: safety first. (2021) (0)
- Abstract 4396: Multiomics assessment of the cancer and stromal compartments of patient-derived pancreatic xenografts reveals clinically-relevant subtypes and novel targeted therapies (2017) (0)
- Bleeding anal varix: adverse effects of local treatment with histoacryl. (1992) (0)
- Survival after cytoreductive surgery for peritoneal metastases in colorectal cancer patients: Does a history of resected liver metastases worsen the prognosis? (2021) (0)
- [Palliative treatment for hepatocellular carcinoma]. (2013) (0)
- [Digestive hemorrhage following gastroduodenal ulcers caused by non-steroidal anti-inflammatory agents]. (1991) (0)
- [Isolated fever disclosing Crohn disease. Diagnostic contribution of scintigraphy with Tc 99m HMPAO labelled leukocytes]. (1989) (0)
- [Nuclear medicine in oncology: new diagnostic and therapeutic methods]. (2001) (0)
- Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial. (2017) (0)
- [Successful treatment of fulminant Crohn's colitis with azathioprine]. (1991) (0)
- Hepatocellular carcinoma with portal vein thrombosis treated with yttrium-90 microsphere radioembolization results on 22 consecutive patients. (2011) (0)
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : Subanalyses of a phase III trial q , qq (2012) (0)
- Peritoneal Carcinomatosis of Hepatocellular Carcinoma After Resection-Efficacy of Complete Surgical Resection with Hyperthermic Intraperitoneal Chemotherapy (2020) (0)
- Absence of human papillomavirus DNA sequences in oesophageal mucosa of French patients with oesophageal squamous-cell carcinoma (1995) (0)
- Author Index / Subject Index, Vol. 13, 1995 (1995) (0)
- Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome (2015) (0)
- Table of Contents for (9781402088995) Methods of Cancer Diagnosis, Therapy and Prognosis: Gastrointestinal Cancer by Hayat, M. A (2011) (0)
- [Diffuse pseudopolyposis of the colon: developmental form or cicatricial of hemorrhagic rectocolitis?]. (1988) (0)
- [Relation of the kinetics of the antisecretory effect and kinetics of blood concentration in man. Comparing cimetidine and ranitidine]. (1989) (0)
- Prediction of benefit after transarterial chemoembolization (TACE): Subclassifications or scoring systems? (2018) (0)
- Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). (2016) (0)
- Familial linitis plastica: Identification of a hitherto unreported germline E-cadherin mutation (2000) (0)
- Recurrent Oxaliplatin-Induced Immune Hemolytic Anemia by Chemotherapy for Metastatic Colon Cancer: A Case Report * (2013) (0)
- Geriatric profile of elderly patients treated for pancreatic cancer (2014) (0)
- [First-line metastatic cancer of the colon]. (2003) (0)
- COVID-19-Related Symptoms Among Cancer Patients and Healthcare Workers— First Results From the PAPESCO-19 Prospective Cohort Study (2021) (0)
- Pneumonia : A Series of 15 Cases I-Labeled Lipiodol-Induced Interstitial 131 (2011) (0)
- Pneumopathies secondaires à l'injection de lipiodol radioactif ou lipiocis® (2008) (0)
- [Comment on a case report. Recurrent dysphagia]. (1999) (0)
- “Posterior” gastric vein, okay. But let's not forget the “Collateral” gastric vein (1991) (0)
- COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19) (2022) (0)
- [Severe interstitial pneumopathy due to herpes virus after radiochemotherapy for esophageal carcinoma]. (2001) (0)
- CAS CLINIQUE Tonsillar metastasis revealing signet-ring cell carcinoma of the rectum A case report (2005) (0)
- Adjuvant treatment after resection of biliary-tract cancer: yes or no? (2011) (0)
- Abstract A48: Multi-omics characterization of PDAC subtypes using PDX reveals that epigenetic but not genetic analysis permit a clinically relevant classification (2016) (0)
- Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. (2023) (0)
- Other causes of distal esophageal ballooning. (1989) (0)
- [Medical treatment of a voluminous tumor of the mesenteric root]. (2003) (0)
- Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer (2011) (0)
- Modalities and indications of locoregional treatments in digestive neuroendocrine tumours (2012) (0)
- Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions. (2018) (0)
- Reply: (2005) (0)
- [Epithelial transport. From proton pump to epithelial endocytosis]. (1990) (0)
- [Patient participation in medical decision-making: From concept to reality in oncology]. (2017) (0)
- [Diagnosis of lesions in upper digestive hemorrhage related to portal hypertension]. (1990) (0)
- Angiographic demonstration of esophagojejunal venous shunt in a patient with esophagojejunostomy and esophageal varices. (1989) (0)
- 6127 POSTER What About Risk Factors KRAS, BRAF and PI3K in a French Translational Study OMIT of 325 Patients Traited With Cetuximab Based-regimen in Real Practice (2011) (0)
- 18-FDG-PET and somatostatin receptor scintigraphy (SRS) can predict disease progression and survival in patients with metastatic endocrine tumors: Results of a prospective study (2007) (0)
- P-037Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single Cancer Institution (2015) (0)
- [Neoadjuvant treatment in surgery of esophageal cancer]. (2000) (0)
- Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology) (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jean‐luc Raoul?
Jean‐luc Raoul is affiliated with the following schools:
